A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)-Reference-Cited by-同舟云学术

A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Published:2021-07-21 Issue:13 Volume:62 Page:3181-3191
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Webster Jonathan A.¹^ORCID,Yogarajah Meera²,Zahurak Marianna³,Symons Heather¹,Dezern Amy E.¹,Gojo Ivana¹,Prince Gabrielle T.¹,Morrow Jillian¹,Jones Richard J.¹,Smith B. Douglas¹,Showel Margaret¹

Affiliation:

1. Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

2. SSM Medical Group, St. Charles, MO, USA

3. Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Funder

NIH

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1948029

Reference62 articles.

1. Age and acute myeloid leukemia